Romosozumab
Based on 1 publication(s) in Google Scholar
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.11%
- CAS No.: 909395-70-6
- 분자량:146.32 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Romosozumab
More
Customer Validation & Images
-
Cell Imaging/Staining
Biological Activity
제품 설명
Isotype
Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
SOST/Sclerostin
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male cynomolgus monkeys[1]
-
Dosage:30 mg/kg
-
Administration:Subcutaneous injection; 30 mg/kg twice a week for 10 weeks
-
Result:Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG2 kappa
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized SOST Protein, Human can bind Romosozumab. The EC50 for this effect is 12.46 ng/mL.
Chemical Information
-
CAS No. 909395-70-6
-
Appearance Liquid
-
분자량 146.32 kDa
-
Color Colorless to light yellow
-
SMILES
[Romosozumab]
-
Synonyms
AMG-785; CDP-7851
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Schisandrol B inhibits osteoclastogenesis and mitigates estrogen deficiency-induced bone loss by targeting TRAF6-NOX1 pathway. [Abstract]2026 Jan:150:157669. PMID: 41435606
Romosozumab purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jan:150:157669. [Abstract]
Representative images of mature OCs (nuclei≥3) treated with SolB, Denosumab, and Romosozumab (5 μM) and quantitation of mature OCs.
순도&문서
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Paik J, Scott LJ. Romosozumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2020 Nov;37(11):845-855. [Content Brief]
[2]. Ominsky MS, et al. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys. J Bone Miner Res. 2017 Apr;32(4):788-801. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Romosozumab Related Classifications
HY-P9982 Related Classifications
Powered by Bioz